图片来源:视觉中国界面新闻记者 |黄华界面新闻编辑 |谢欣健友股份日前公告称,旗下利拉鲁肽注射液于近日被美国食品药品监督管理局(简称“美国FDA”)批准用于2型糖尿病治疗。利拉鲁肽注射液原研药品由诺和诺德研发。原研产品于2010年1月25日前经FDA批准在美国上市,商品名为“Victoza”,规格为:18 mg/3 mL (6 mg/mL)。健友股份在公告中表示,新批准产品近期将安排在美国上市销售...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.